Immunohistochemical analysis indicated positivity for estrogen receptor, progesterone receptor, HER2/neu, and a Ki67 proliferation index of 60%, categorizing this breast cancer molecularly as luminal B HER2-positive subtype. The gene discussed is ERBB2; the disease is breast carcinoma.